Ti(3)C(2) MXene-Coated Germanium Nanoparticles on Nickel Foam for Binder-Free Lithium-Ion Battery Anodes.

Acute pulmonary embolism (PE) is a major cause of morbidity and mortality and the third leading cause of cardiovascular death []. Catheter directed thrombolysis (CDT) was utilized to minimize bleeding complications through localized delivery of thrombolytics using lower dosages of thrombolytics over a prolonged duration. CDT is currently used primarily in patients with intermediate-high and high-risk pulmonary embolism []. These therapies were not developed to replace systemic thrombolysis but rather to provide alternative reperfusion strategies using localized thrombolytic delivery or large-bore aspiration systems adapted from technologies long used in other vascular territories. Systemic thrombolysis and CDT have historically been used to improve RV dysfunction compared to anticoagulation alone [–]. Mechanical thrombectomy was introduced as an endovascular option to avoid thrombolytics and may be considered in patients with shock, failed thrombolysis, or bleeding risk []. Despite increased adoption of mechanical thrombectomy for both intermediate- and high-risk PE, data directly comparing mechanical thrombectomy to CDT with respect to clinical outcomes and adverse events have been limited. Several retrospective cohort studies, the PEERLESS randomized controlled trial, and subsequent real-world analyses have addressed this comparison [–]. Concurrently, the HI-PEITHO trial and others have provided new evidence for catheter-based reperfusion strategies against anticoagulation alone []. The primary objective of this study was to utilize the Nationwide Readmissions Database (NRD) to compare CDT and mechanical thrombectomy for acute high- and intermediate-risk PE with respect to unplanned 6-month readmissions and outcomes.